Among current techniques for clinical genome editing, the CRISPR-associated gene editing system has emerged as a highly advantageous method to drive development of new gene and cell therapies. Through evolving routes of direct delivery of the CRISPR-ribonucleoprotein (RNP) complex, consisting of single guide RNA (sgRNA) and Cas nucleases, a non-viral approach has become increasingly in demand for gene-editing clinical trials. However, drug developers face significant challenges when initiating their clinical programs, which includes the design and production of the target-specific guides, the production of reliable, high-quality nucleases, and the ability to characterize the RNP complex for the efficient and safe delivery of a genomic therapy.
In this webinar, Oat Khodthong, PhD from Aldevron and Garrett Rettig, PhD from Integrated DNA Technologies (IDT) will highlight how our partnership and services will accelerate new CRISPR-based therapies to support genomic medicine. IDT will spotlight their capabilities in chemistry and oligo production for high-quality CRISPR gRNAs, while Aldevron will detail an expertise in cGMP CRISPR nuclease and RNP manufacturing and characterization*. We have brought our synergistic services together to provide drug development partners with complete CRISPR genome editing solutions.
*Aldevron provides RNPs only to customers who are duly licensed, including to make and have made RNPs, for their intended use.
Oat Khodthong, PhD, is a Senior Scientist in the Research & Development department at Aldevron with a focus on analytical method development, located at the Madison, Wisconsin site. Oat received a Ph.D. in Neuroscience from the University of Wisconsin-Madison in 2010 and has more than 12 years of experience in gene editing and analytical method development in biotechnology and pharmaceutical industries.
Garrett Rettig, PhD, is the Senior Director of Product Development in the Molecular Genetics Research department at Integrated DNA Technologies. During his time at IDT, Garrett has been a lead scientist on various RNA knockdown projects – particularly high-throughput screening of siRNAs and chemical modifications thereof. For the past 6 years, the focus of the team has shifted to improving methods and developing new technologies for CRISPR-mediated genome editing. In particular, Garrett's work in this area has had an emphasis on assessing editing with NGS applications.
As head of the client success team at Endpoints News, Kari oversees campaign delivery and strategy for all advertising and client-directed webinars. She brings nearly 20 years of diverse experience across strategic communications, content development and operational leadership.